Why the study?
TLR4 plays an important role in cardiovascular disease and cardiac inflammation, motivating an investigation into its role in Ang II-induced cardiac hypertrophy.
Does TAK-242 reduce Angiotensin II-induced cardiac hypertrophy in a mouse model?
Does TAK-242 reduce Angiotensin II-induced cardiac hypertrophy in a mouse model?
In a mouse model, the TLR4 inhibitor TAK-242 attenuated Angiotensin II-induced cardiac hypertrophy and fibrosis, highlighting TLR4 as a potential therapeutic target for myocardial remodeling.
TLR4 inhibition should not yet change clinical practice in hypertrophy; leaves open mechanistic validation in human models.
Background and Objective: The TLR4 plays an important role in the development of cardiovascular disease and is closely related to cardiac inflammation.This study aimed to investigate the role of TLR4 in Ang II-induced cardiac hypertrophy.Materials and Methods: The Ang II-induced cardiac hypertrophy model in C57BL/6 male mice was established and treated with TAK-242 for 4 weeks.The cross-sectional area of cardiomyocytes was evaluated by Hematoxylin and Eosin (H&E) staining.Cardiac fibrosis was measured with Masson staining.Vimentin expression was detected by immunohistochemistry.The mRNA expression of TLR4 was analyzed by RT-qPCR.Results: The Ang II-increased cardiac mass index, cardiactibial ratio, cross-sectional area of cardiomyocytes and cardiac fibrosis as well as vimentin and TLR4 expression.Administration of TAK-242 attenuated these effects induced by Ang II.Conclusion: The TLR4 plays a vital role in Ang II-induced cardiac hypertrophy.It provides a new target for the future treatment of cardiac hypertrophy.
No takes yet. Share an insight, caveat, or question.
Shang et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: